D.C. medical cannabis sales reach $10.25 million in September, up 31% from a year earlier

Washington, D.C.'s medical cannabis program recorded $10,245,823 in sales in September 2026, up from $9,846,506 in August and $7,821,780 in September 2025, according to the September 2026 Medical Cannabis Program Report from the District's Alcoholic Beverage and Cannabis Administration (ABCA). The Marijuana Herald, which reported the figures on Oct. 16, calculated the year-over-year gain at 31% and put combined sales for the first nine months of 2026 at $88,059,639.

Licensed dispensaries accounted for $6,357,934 of September's total, compared with $5,227,030 a year earlier, the ABCA report shows. Cultivation centers reported $809,460 and manufacturers $3,078,429, both up from September 2025.

The report lists 149,199 registered D.C. resident patients in September, up from 143,556 in August, and 67 retailers, up from 66. Unique patients served by registered dispensaries rose to 40,736 from 39,382. Purchases by D.C. residents totaled $3,938,876, while self-certified temporary patients from outside the District accounted for $1,994,471 and patients using reciprocity accounted for $424,587, according to the report.

Flower remained the largest retail category at $3,181,101, followed by vape cartridges at $1,173,678 and infused edibles at $759,904. The report's beverage line shows figures only for September: 1,014 beverages sold for $11,834.

On enforcement, the report lists no violations observed and no facilities closed in September, with seven scheduled inspections and 3,329 pounds of cannabis waste destroyed.

This report summarizes published government data and is not legal or medical advice.